Now Pfizer rolls-out app for patient assistance programmes
Patient access program is being executed by Tata 1MG16-12-2022
16-12-2022
Pfizer expects $10 bn- $15 bn in annual mRNA vaccine revenue by 2030
Pfizer said sales from its respiratory syncytial virus (RSV) vaccine candidate, which it expects to launch in 2023, could peak in 2027 and reach more than $2 billion13-12-2022
PFIZER LTD. - 500680 - Disclosure Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2022. The said disclosure is also available on the website of the Company i.e., www.pfizerltd.co.in Please take the above on record25-11-2022
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Limited has received below mentioned requests for issue of duplicate Share Certificate(s) from Shareholders. We shall issue the letter of confirmation(s) upon completion of necessary formalities by the shareholders. Please take the above on record.23-11-2022
Glenmark, Pfizer ink settlement on kidney cancer drug Axitinib
This could stagger or delay launch of the product in the US, say observers22-11-2022
Pfizer India Q2 PAT rises to Rs 226 crore on lower costs, price hikes
Its cost of materials consumed fell 2.1% to Rs 94.4 crore, accounting for about 21% of total expenses in the quarter11-11-2022
PFIZER LTD. - 500680 - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter and half year ended September 30, 2022. The said results were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.15 p.m. and concluded at 4.00 p.m. Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co., LLP, in respect of the above results. Please take the above on record11-11-2022
PFIZER LTD. - 500680 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agent of the Company, KFin Technologies Limited has received requests for issue of duplicate Share Certificate(s) from Shareholder(s). We shall issue the Letter of Confirmation(s) upon completion of necessary formalities by the shareholder(s). Please take the above on record.09-11-2022
BioNTech Q3 earnings drop but forecast for vaccine revenue grows
BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, reported that its earnings in the third quarter were close to half what they were a year earlier, but the German pharmaceutical company still raised its expectations for vaccine revenue after rolling out updated shots targeting omicron strains. The company said Monday that it made net profit of 1.8 billion euros (USD 1.8 billion) off revenue of 3.5 billion euros (USD 3.5 billion) in the three months to September, a drop from profit of 3.2 billion euros and revenue of 6.1 billion euros in the same period a year ago. BioNTech said the course of the pandemic remains dynamic and led to fluctuations" in earnings. Profit and revenue were largely flat in the first nine months of the year. Thanks to our strong execution in the third quarter of 2022, we updated our COVID-19 vaccine revenue guidance for the year 2022 to the upper end of the original range," said Jens Holstein, CFO of BioNTech. We started shipments of o07-11-2022